Crossmark

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC

Crossref DOI link: https://doi.org/10.1186/s12916-021-02118-x

Published Online: 2021-10-19

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Yongchang

Zeng, Liang

Zhang, Xiangyu

Li, Yizhi

Liu, Lingli

Xu, Qinqin

Yang, Haiyan

Jiang, Wenjuan

Lizaso, Analyn

Qiu, Luting

Hou, Ting

Liu, Jun

Peng, Ling

Yang, Nong
Funding

Funding for this research was provided by:

hunan provincial science and technology department (2018RS3106, 2018SK50901, kq1801102, 2019-TJ-N04, 2019JJ50357, 2019SK4010, 2020JJ5340, 2020JJ3025)
License Information

Text and Data Mining valid from 2021-10-19

Version of Record valid from 2021-10-19
More Information

Article History

Received: 11 July 2021

Accepted: 3 September 2021

First Online: 19 October 2021

Declarations

:

: Approval was obtained from the Hunan Cancer Hospital Institutional Review Board Committee (2017YYQ-SSB-159). All patients provided written informed consent for the use of their clinical and molecular data for research purposes.

: Not applicable

: AL, LQ, and TH are employed by Burning Rock Biotech. All the other authors declare no conflict of interest.

Document is current

Any future updates will be listed below